

# CLINICAL TRIAL FACT SHEET

## Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

**This study is currently recruiting participants.**

*Sponsored by:* Merck

*Information provided by:* Merck

*ClinicalTrials.gov Identifier:* NCT00773838

*Merck study ID number:* Vantage 095

### Purpose

Study of vorinostat in combination with bortezomib in patients with relapsed or refractory multiple myeloma after at least 2 prior treatment regimens.

### Eligibility

18 Years and older

Genders Eligible for Study: Both

Accepts Healthy Volunteers: No

#### Inclusion Criteria:

- Patient is 18 years of age or older
- Patient has an established diagnosis of multiple myeloma based on myeloma diagnostic criteria and received at least 2 prior anti-myeloma regimens
- Patient must have adequate organ function
- Patient is refractory to prior bortezomib regimen and has also been exposed to prior IMiD (thalidomide or lenalidomide)

#### Exclusion Criteria:

- Patient has known hypersensitivity to any components of bortezomib or vorinostat
  - Patient has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation within 4 weeks of the initiation of study therapy
  - Patient has known hypersensitivity to any components of bortezomib or vorinostat.
- Patient has active Hepatitis B or C, plasma cell leukemia, or is HIV positive

### Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00773838

**Contacts:** *Contact:* Toll Free Number 1-888-577-8839

#### Locations

##### *United States, Indiana*

Call for Information **Recruiting**  
Indianapolis, Indiana, United States, 46254

##### *United States, Massachusetts*

Call for Information **Recruiting**  
Boston, Massachusetts, United States, 02115

##### *United States, Missouri*

Call for Information **Recruiting**  
Jefferson City, Missouri, United States, 65109-0000

*(continues on next page)*



#### **International Myeloma Foundation**

12650 Riverside Drive, Suite 206, North Hollywood, CA 91607 USA

Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 (worldwide) • TheIMF@myeloma.org • www.myeloma.org

***United States, New Jersey***

Call for Information **Recruiting**  
Hackensack, New Jersey, United States, 07601

***United States, New York***

Call for Information **Recruiting**  
Syracuse, New York, United States, 13210-0000

Call for Information **Recruiting**  
New York, New York, United States, 10011

***United States, Tennessee***

Call for Information **Recruiting**  
Knoxville, Tennessee, United States, 37920

***Australia***

Merck Sharp & Dohme (Australia) Pty Ltd. **Recruiting**  
South Granville, Australia, NSW 2142  
Contact: David Woolner 64-9-523-6075

***Belgium***

Merck Sharp & Dohme B.V. **Recruiting**  
Bruxelles, Belgium, 1180  
Contact: Nathalie Schrameijer 32-2-373-4310

***Canada, Quebec***

Merck Frosst Canada Ltd. **Recruiting**  
Kirkland, Quebec, Canada, H9H 3L1  
Contact: Michel Cimon 514-428-2605

***France***

Laboratoires Merck Sharp & Dohme - Chibret **Recruiting**  
Paris Cedex 8, France, 75114  
Contact: Jean-Marie Goehrs 33-1-4754-89-90

***Italy***

Merck Sharp & Dohme (Italia) S.P.A. **Recruiting**  
Roma, Italy, 191  
Contact: Gianfranco Botta 39 06 36 191187

***Korea, Republic of***

MSD Korea Ltd. **Recruiting**  
Seoul, Korea, Republic of, 121-705  
Contact: Steve Kim 82-2-6363-0241

***Spain***

Merck Sharp & Dohme De Espana, S.A.E. **Recruiting**  
Madrid, Spain, 28027  
Contact: Jorge Gonzalez-Esteban 34-91-3210-728

**Sponsors and Collaborators**

Merck

**Investigators**

Study Director: Medical Monitor Merck

**International Myeloma Foundation**

12650 Riverside Drive, Suite 206, North Hollywood, CA 91607 USA

Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 (worldwide) • TheIMF@myeloma.org • www.myeloma.org